Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('Ecstasy') cytotoxicity.

Pharmacogenetics and genomics - 1 Nov 2006

Carmo Helena, Brulport Marc, Hermes Matthias, Oesch Franz, Silva Renata, Ferreira Luísa M, Branco Paula S, Boer Douwe de, Remião Fernando, Carvalho Félix, Schön Michael R, Krebsfaenger Niels, Doehmer Johannes, Bastos Maria de Lourdes, Hengstler Jan G

Abstract excerpt

OBJECTIVES: Remarkable interindividual differences in 3,4-methylenedioxymethamphetamine ('Ecstasy')-mediated toxicity have been reported in humans. Therefore, we tested whether CYP2D6 or its variant alleles as well as CYP3A4 influence the susceptibility to 3,4-methylenedioxymethamphetamine. METHO...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dose-Response Relationship, Drug
Share to Catalysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cricetinae

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 CYP3A

Share to Cytochrome P-450 Enzyme System

Share to Models, Biological

Share to Oxidation-Reduction

Source

Identifiers

PMID: 17047487
DOI: 10.1097/01.fpc.0000230419.05221.fc

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17047487-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('Ecstasy') cytotoxicity.PMID 17047487Read ↗

CYP2D6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA).Semantic proximity Read ↗

CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.Semantic proximity Read ↗

Fatal intoxication cases: cytochrome P450 2D6 and 2C19 genotype distributions.Semantic proximity Read ↗

Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.Semantic proximity Read ↗

Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT)Semantic proximity Read ↗

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects.Semantic proximity Read ↗

Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity.Semantic proximity Read ↗

Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles.Semantic proximity Read ↗

The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.Semantic proximity Read ↗

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.Semantic proximity Read ↗

Is toxicity of PMMA (paramethoxymethamphetamine) associated with cytochrome P450 pharmacogenetics?Semantic proximity Read ↗

Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.